You just read:

Bayer's Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

News provided by

Bayer HealthCare Pharmaceuticals

Sep 25, 2013, 08:30 ET